Acridine carboxamide
Acridine carboxamide is a chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C8H19N3O |
Molar mass | 293.363 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]
See also
- Ondansetron, an isomer of Acridine carboxamide
References
- Dittrich C, Dieras V, Kerbrat P, et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs. 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID 14578683.
- Caponigro F, Dittrich C, Sorensen JB, et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer. 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842.
- Twelves C, Campone M, Coudert B, et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. doi:10.1093/annonc/mdf121. PMID 12075748.
- Dittrich C, Coudert B, Paz-Ares L, et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer. 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.